High-Octane Growth at Fidelity Growth Company
Manager Steve Wymer invests in a range of stocks but favors fast-growing tech health-care companies.
Editor's note: This is part of a continuing series of articles looking at the 20 biggest no-load stock funds.
You don't have to be little to invest aggressively, as Fidelity Growth Company proves. Steve Wymer, manager of the $29 billion fund since 1997, focuses most of his attention on fast-growing technology and health-care stocks. Each sector accounts for a third of the fund's 275 holdings. The fund, which closed to new investors in April 2006, focuses on companies with rapid revenue growth and stock-market values of more than $1 billion. "The theory is when revenue is growing, potential is there," says Wymer. "But I don't chase growth for growth's sake. I invest in good businesses that will be profitable in the long term."
Wymer searches for what he calls "self-help stories." These are companies improving their business through acquisitions and management changes. He also seeks companies that are in the midst of product cycles that will spark revenue growth. One example: Japan's Nintendo (symbol NTDOY), which recently launched the game console Wii. And he invests in spin-offs, such as Ameriprise Financial (AMP), which American Express jettisoned in 2005.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
In technology, Wymer focuses on niches he thinks have high-growth potential, including wireless technology and Internet search. The fund's top spot, as of September 30, was Google (GOOG). Wymer is betting on the success of the company's advertising platform, in which ads are tailored to each particular viewer. "Google represents one of the best areas of technology," Wymer says. Elsewhere in the tech sector, he likes companies that deal in software-related services, such as Red Hat (RHAT), which gives away the Linux operating system and charges customers for support and consulting services. In health care, Wymer focuses on three areas: biotechnology, diagnostics, and health-care technology. "I'm looking for companies that can grow if health-care spending goes up," says Wymer. Two companies he favors in that realm are biopharmaceutical firms Celgene (CELG) and Elan (ELN).
With Wymer behind the wheel, Growth Company has delivered solid results over the long term. Over the past decade, the fund's 9% annualized return was better than the results of 93% of funds that focus on large, fast-growing companies. But Growth Company can take shareholders on a bumpy ride. The fund has been 25% more volatile than its rivals and can crash when high-octane companies fall out of favor. During the 2000-02 bear market, the fund plunged 69%, compared with a 47% decline for the S&P 500.
Still, given Wymer's fine record versus his peers and our view that large-company growth stocks represent one of the most attractive segments of the market, we suggest that shareholders continue to BUY Growth Company.
FUND FACTS
Fidelity Growth Company (FDGRX)
Assets: $29.2 billion
Managers (year started): Steve Wymer (1997)
Return (vs. S&P 500):
Year to date: 8.0% (12.6%)
One year: 7.9% (11.0%)
Three years annualized: 11.8% (11.3%)
Five years annualized: 5.1% (4.7%)
Ten years annualized: 9.5% (8.6%)
Expense ratio: 0.96%
Portfolio turnover: 50%
Minimum investment: closed
Phone: 800-544-8544
Web site: www.fidelity.com
Data is to Nov. 28
Fund Fact sources: Standard & Poor's, Morningstar
View updated data for this fund and compare the performance of the 20 biggest no-load stock funds.
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
-
Stock Market Today: Stocks End Higher in Whipsaw Session
The main indexes were volatile Thursday with Nvidia earnings in focus.
By Karee Venema Published
-
Trump Picks Dr. Oz as Head of Medicare and Medicaid
President-elect Donald Trump picked Dr. Mehmet Oz to lead the Centers for Medicare and Medicaid Services. Here's what to know about the former TV host.
By Kathryn Pomroy Published
-
The 5 Best Actively Managed Fidelity Funds to Buy Now
mutual funds In a stock picker's market, it's sometimes best to leave the driving to the pros. These Fidelity funds provide investors solid active management at low costs.
By Kent Thune Last updated
-
The 12 Best Bear Market ETFs to Buy Now
ETFs Investors who are fearful about the more uncertainty in the new year can find plenty of protection among these bear market ETFs.
By Kyle Woodley Published
-
Don't Give Up on the Eurozone
mutual funds As Europe’s economy (and stock markets) wobble, Janus Henderson European Focus Fund (HFETX) keeps its footing with a focus on large Europe-based multinationals.
By Rivan V. Stinson Published
-
Best Bond Funds to Buy
Investing for Income The best bond funds provide investors with income and stability – and are worthy additions to any well-balanced portfolio.
By Jeff Reeves Last updated
-
Vanguard Global ESG Select Stock Profits from ESG Leaders
mutual funds Vanguard Global ESG Select Stock (VEIGX) favors firms with high standards for their businesses.
By Rivan V. Stinson Published
-
Kip ETF 20: What's In, What's Out and Why
Kip ETF 20 The broad market has taken a major hit so far in 2022, sparking some tactical changes to Kiplinger's lineup of the best low-cost ETFs.
By Nellie S. Huang Published
-
ETFs Are Now Mainstream. Here's Why They're So Appealing.
Investing for Income ETFs offer investors broad diversification to their portfolios and at low costs to boot.
By Nellie S. Huang Published
-
Do You Have Gun Stocks in Your Funds?
ESG Investors looking to make changes amid gun violence can easily divest from gun stocks ... though it's trickier if they own them through funds.
By Ellen Kennedy Published